

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Noxopharm Limited
ABN	50 608 966 123

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Marks
Date of last notice	28 September 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	4 June 2020
No. of securities held prior to change	<p><u>DIRECT</u> N/A</p> <p><u>INDIRECT</u> Shanti Capital Pty Ltd <Peter Marks Super A/C></p> <ol style="list-style-type: none"> 1. 500,000 ordinary shares 2. 200,000 unlisted options \$0.30, expiry 28/2/2021 3. 250,000 unlisted options \$1.0158, expiry 27/11/2020 4. 250,000 unlisted options \$1.2189, expiry 27/11/2020

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Class	<ul style="list-style-type: none"> 3. unlisted options \$1.0158, expiry 27/11/2020 4. unlisted options \$1.2189, expiry 27/11/2020
Number acquired	N/A
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	N/A
No. of securities held after change	<p><u>DIRECT</u> N/A</p> <p><u>INDIRECT</u> Shanti Capital Pty Ltd <Peter Marks Super A/C></p> <ul style="list-style-type: none"> 1. 500,000 ordinary shares 2. 200,000 unlisted options \$0.30, expiry 28/2/2021 3. 250,000 unlisted options \$0.996271, expiry 27/11/2020 4. 250,000 unlisted options \$1.199371, expiry 27/11/2020
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<p>No change in security numbers. As announced on 28 May 2020, further to Listing Rule 6.22.2, the exercise price of some options held has changed as follows:</p> <ul style="list-style-type: none"> 3. \$1.0158 to \$0.996271 4. \$1.2189 to \$1.199371

+ See chapter 19 for defined terms.

For personal use only

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

For personal use only